$1.87
Live
1.07%
Downside
Day's Volatility :4.64%
Upside
3.61%
48.51%
Downside
52 Weeks Volatility :74.49%
Upside
50.44%
Period | Cellectis S.a. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -9.09% | 3.6% | 0.0% |
6 Months | -28.03% | 10.2% | 0.0% |
1 Year | 58.33% | 19.6% | 0.0% |
3 Years | -83.08% | 16.8% | -23.0% |
Market Capitalization | 199.5M |
Book Value | $1.49 |
Earnings Per Share (EPS) | -1.23 |
PEG Ratio | 0.0 |
Wall Street Target Price | 7.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -181.11% |
Return On Assets TTM | -17.3% |
Return On Equity TTM | -64.37% |
Revenue TTM | 19.6M |
Revenue Per Share TTM | 0.28 |
Quarterly Revenue Growth YOY | 374.90000000000003% |
Gross Profit TTM | 24.0M |
EBITDA | -77.4M |
Diluted Eps TTM | -1.23 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.79 |
EPS Estimate Next Year | -0.69 |
EPS Estimate Current Quarter | -0.3 |
EPS Estimate Next Quarter | -0.26 |
What analysts predicted
Upside of 274.33%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 12.7M | ↓ 49.46% |
Net Income | -78.7M | ↓ 20.81% |
Net Profit Margin | -618.12% | ↓ 223.61% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 15.2M | ↑ 19.32% |
Net Income | -90.7M | ↑ 15.24% |
Net Profit Margin | -597.01% | ↑ 21.11% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 73.9M | ↑ 386.83% |
Net Income | -72.6M | ↓ 19.98% |
Net Profit Margin | -98.14% | ↑ 498.87% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 73.9M | ↑ 0.0% |
Net Income | -86.3M | ↑ 18.89% |
Net Profit Margin | -116.68% | ↓ 18.54% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 19.2M | ↓ 74.08% |
Net Income | -98.7M | ↑ 14.38% |
Net Profit Margin | -514.78% | ↓ 398.1% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 755.0K | ↓ 96.06% |
Net Income | -101.1M | ↑ 2.4% |
Net Profit Margin | -13.4K% | ↓ 12870.52% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 139.0K | ↓ 99.13% |
Net Income | -30.1M | ↑ 17.01% |
Net Profit Margin | -21.6K% | ↓ 21475.57% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 155.0K | ↑ 11.51% |
Net Income | -17.5M | ↓ 41.87% |
Net Profit Margin | -11.3K% | ↑ 10357.26% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 283.0K | ↑ 82.58% |
Net Income | -42.9M | ↑ 145.18% |
Net Profit Margin | -15.1K% | ↓ 3866.87% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 283.0K | ↑ 0.0% |
Net Income | -42.9M | ↑ 0.0% |
Net Profit Margin | -15.1K% | ↑ 0.0% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 4.5M | ↑ 1500.0% |
Net Income | 5.6M | ↓ 113.17% |
Net Profit Margin | 124.62% | ↑ 15270.2% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 8.1M | ↑ 78.03% |
Net Income | -25.3M | ↓ 547.81% |
Net Profit Margin | -313.48% | ↓ 438.1% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 500.8M | ↑ 50.46% |
Total Liabilities | 50.6M | ↑ 7.64% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 467.5M | ↓ 6.66% |
Total Liabilities | 112.0M | ↑ 121.48% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 469.5M | ↑ 0.43% |
Total Liabilities | 160.6M | ↑ 43.42% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 382.1M | ↓ 18.62% |
Total Liabilities | 145.6M | ↓ 9.35% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 261.2M | ↓ 31.63% |
Total Liabilities | 135.3M | ↓ 7.09% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 334.3M | ↑ 27.97% |
Total Liabilities | 249.6M | ↑ 84.49% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 251.4M | ↓ 3.75% |
Total Liabilities | 130.9M | ↓ 3.22% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 209.7M | ↓ 16.59% |
Total Liabilities | 133.6M | ↑ 2.03% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 334.3M | ↑ 59.4% |
Total Liabilities | 249.6M | ↑ 86.84% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 334.3M | ↑ 0.0% |
Total Liabilities | 249.6M | ↑ 0.0% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 354.5M | ↑ 6.04% |
Total Liabilities | 263.9M | ↑ 5.74% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 407.1M | ↑ 14.86% |
Total Liabilities | 258.5M | ↓ 2.03% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -68.1M | ↑ 30.21% |
Investing Cash Flow | 35.6M | ↑ 1896.8% |
Financing Cash Flow | 236.5M | ↑ 473.1% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -69.1M | ↑ 1.47% |
Investing Cash Flow | -35.9M | ↓ 200.7% |
Financing Cash Flow | -3.9M | ↓ 101.63% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -80.3M | ↑ 16.08% |
Investing Cash Flow | -54.3M | ↑ 51.49% |
Financing Cash Flow | 27.3M | ↓ 807.46% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -104.6M | ↑ 30.28% |
Investing Cash Flow | 7.3M | ↓ 113.39% |
Financing Cash Flow | 47.5M | ↑ 73.94% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -87.4M | ↓ 16.37% |
Investing Cash Flow | -2.8M | ↓ 137.93% |
Financing Cash Flow | 1.1M | ↓ 97.59% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -28.3M | ↑ 2221.8% |
Investing Cash Flow | -1.8M | ↑ 0.0% |
Financing Cash Flow | 19.8M | ↓ 492.3% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -17.1M | ↓ 39.65% |
Investing Cash Flow | -1.8M | ↑ 0.0% |
Financing Cash Flow | 1.7M | ↓ 91.47% |
Sell
Neutral
Buy
Cellectis S.a. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Cellectis S.a. | -13.64% | -28.03% | 58.33% | -83.08% | -81.75% |
Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Cellectis S.a. | NA | NA | 0.0 | -0.79 | -0.64 | -0.17 | NA | 1.49 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Cellectis S.a. | Buy | $199.5M | -81.75% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Cellectis S.a.
Revenue is up for the last 6 quarters, 139.0K → 8.06M (in $), with an average increase of 38.6% per quarter
Netprofit is down for the last 2 quarters, 5.64M → -25.27M (in $), with an average decrease of 547.8% per quarter
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 25.9%
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 127.9%
Long Focus Capital Management, LLC
Capital Research & Mgmt Co - Division 3
UBS Asset Mgmt Americas Inc
Credit Suisse First Boston (CSFB)
Baillie Gifford & Co Limited.
Principal Financial Group Inc
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.
Organization | Cellectis S.a. |
Employees | 216 |
CEO | Dr. Andre Choulika Ph.D. |
Industry | Health Technology |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$1.87
-1.58%
Invesco Bulletshares 2025 Hi
$1.87
-1.58%
Schwab International Dividend Equity Etf
$1.87
-1.58%
Blockchain Coinvestors Acquisition Corp.
$1.87
-1.58%
Allgiant Travel Company
$1.87
-1.58%
Rogers Corp
$1.87
-1.58%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$1.87
-1.58%
Iheartmedia
$1.87
-1.58%
Lightpath Technologies Inc
$1.87
-1.58%